CRISPR Therapeutics Reports $581.6M Loss, Advances Gene Editing Pipeline

CRISPR Therapeutics AG has released its 2025 10-K report, detailing significant financial losses alongside continued advancements in its gene-editing therapeutic pipeline. The company reported a net loss of $581.6 million for the year, an increase from the previous year primarily due to higher operating expenses and a decrease in other income, with total revenue of just $3.5 million reflecting no collaboration revenue recognized in 2025.

The company achieved a significant milestone in 2023 with the approval of CASGEVY, the first-ever CRISPR-based gene-editing therapy, for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia in multiple countries including the United States, European Union, and Canada. The company's product portfolio spans therapeutic programs across various disease areas, including oncology, rare diseases, and regenerative medicine.

CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across four core franchises: hemoglobinopathies, in vivo approaches, CAR T cell therapies, and regenerative medicine, utilizing both ex vivo and in vivo CRISPR-based editing techniques. The company is progressing next-generation CAR T cell therapies, including zugocabtagene geleucel (zugo-cel), which incorporates novel gene edits to enhance potency and reduce exhaustion, targeting autoimmune diseases and oncology.

The company has developed a leading platform for in vivo gene editing, focusing on liver-targeted therapies using lipid nanoparticle delivery technologies. This includes investigational programs like CTX310 for cardiovascular diseases and CTX340 for refractory hypertension. Additionally, the company is advancing siRNA-based clinical-stage programs in collaboration with Sirius Therapeutics, targeting cardiovascular and thromboembolic diseases, with CTX611 being developed as a long-acting FXI inhibitor.

In regenerative medicine, the company is advancing CTX213, a deviceless beta cell replacement product candidate for Type 1 diabetes, utilizing gene edits to promote immune evasion and cell fitness. The company maintains strategic partnerships with Vertex Pharmaceuticals and Sirius Therapeutics to broaden therapeutic applications and accelerate program development, including collaborations on hemoglobinopathies, cystic fibrosis, and siRNA technologies.

Financially, the company reported a loss from operations of $664.6 million, driven by increased operating expenses including acquired in-process research and development expenses. Other income, net was $86.6 million, a decrease from the previous year due to lower interest income earned on cash, cash equivalents, and marketable securities. The company has engaged in multiple capital raising activities, including at-the-market offerings and a registered direct offering, raising significant funds to support its operations.

In 2025, the company issued and sold common shares under the 2021 and 2025 ATM programs, generating net proceeds of $397.3 million. Additionally, a share issuance agreement with Sirius Therapeutics resulted in the issuance of 1,842,105 common shares as partial consideration for a strategic collaboration. The company expects to continue incurring losses as it invests in research and development and seeks regulatory approvals for its product candidates, anticipating that its existing cash, cash equivalents, and marketable securities will fund its operations for at least the next 24 months.

The company is focused on innovating next-generation editing modalities, such as the proprietary SyNTase editing platform, to enhance gene correction efficiency and precision, aiming to expand the potential of gene-based therapeutics. Headquartered in Zug, Switzerland, CRISPR Therapeutics develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform, which allows precise changes to genomic DNA by employing gene editing technology.